ClinicalTrials.gg

Program

remestemcel-l

Also written as “Prochymal®”, “Remestemcel-L-rknd” and “PROCHYMAL®”.

Its studies are mostly in Graft vs Host Disease · Crohn Disease · Diabetes Mellitus, Type 1 · Pulmonary Disease, Chronic Obstructive · Myocardial Infarction, led by 2 companies.

Furthest: phase 3, since Aug 17, 200614 company-led studies, 1 open or runningNext primary completion: Feb 28, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mesoblast131 open or runningphase 3since Aug 17, 2006Aug 25, 2005Feb 28, 2028phase 3 · NCT07568535
EHL Bio10 open or runningphase 1since Aug 15, 2016Aug 15, 2016none ahead

Also a collaborator on its studies: quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2005First study: phase 2 study in Graft vs Host DiseaseNew to MesoblastMesoblast · NCT00136903 · 32 enrolled · United States
  2. Jan 31, 2006Phase 2 study in Graft vs Host DiseaseMesoblast · NCT00284986 · 11 enrolled · United States
  3. Feb 17, 2006Phase 2 study in Crohn DiseaseMesoblast · NCT00294112 · 10 enrolled · United States
  4. Aug 17, 2006Phase 3 study in Graft vs Host DiseaseMesoblast · NCT00366145 · 260 enrolled · United States, Australia, Canada and more
  5. May 30, 2007Phase 3 study in Crohn DiseaseMesoblast · NCT00482092 · 330 enrolled · United States, Australia, Canada and more
  6. Nov 20, 2007Phase 3 study in Graft vs Host DiseaseMesoblast · NCT00562497 · 192 enrolled · United States, Australia, Canada
  7. May 21, 2008Phase 2 study in Pulmonary Disease, Chronic ObstructiveMesoblast · NCT00683722 · 62 enrolled · United States
  8. Jun 2, 2008Phase 2 study in Diabetes Mellitus, Type 1Mesoblast · NCT00690066 · 63 enrolled · United States
  9. Apr 7, 2009Phase 2 study in Myocardial InfarctionMesoblast · NCT00877903 · 220 enrolled · United States, Canada
  10. Nov 2, 2010Phase 3 study in Crohn DiseaseMesoblast · NCT01233960 · 73 enrolled · United States, Australia, New Zealand
  11. Dec 30, 2014Phase 3 study in Grade B aGVHDMesoblast · NCT02336230 · 55 enrolled · United States
  12. Nov 3, 2015Phase 3 study in Grade B Acute Graft Versus Host DiseaseMesoblast · NCT02652130 · 32 enrolled · United States
  13. Aug 15, 2016EHL Bio's first study: phase 1 study in Dermatitis, AtopicNew to EHL BioEHL Bio · NCT02888704 · 13 enrolled · Korea, Republic of
  14. Apr 28, 2026Phase 3 study in Graft vs Host DiseaseMesoblast · NCT07568535 · 180 planned

Ahead

  1. Feb 28, 2028Primary completion: phase 3 study in Graft vs Host DiseaseMesoblast · NCT07568535

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07568535Graft vs Host Disease3Not yet recruitingMesoblastFeb 28, 2028180
NCT02888704Dermatitis, Atopic · Korea, Republic of1CompletedEHL BioDec 201713
NCT02652130Grade B Acute Graft Versus Host Disease · United States3CompletedMesoblastJun 15, 201832
NCT02336230Grade B aGVHD · United States3CompletedMesoblastApr 9, 201855
NCT01233960Crohn Disease · United States, Australia, New Zealand3CompletedMesoblastSep 15, 201473
NCT00877903Myocardial Infarction · United States, Canada2CompletedMesoblastMay 18, 2011220
NCT00690066Diabetes Mellitus, Type 1 · United States2CompletedMesoblastDec 12, 201063
NCT00683722Pulmonary Disease, Chronic Obstructive · United States2CompletedMesoblastMar 9, 200962
NCT00562497Graft vs Host Disease · United States, Australia, Canada3CompletedMesoblastJul 14, 2009192
NCT00482092Crohn Disease · United States, Australia, Canada and more3CompletedMesoblastSep 15, 2014330
NCT00366145Graft vs Host Disease · United States, Australia, Canada and more3CompletedMesoblastDec 26, 2008260
NCT00294112Crohn Disease · United States2CompletedMesoblastJul 21, 200610
NCT00284986Graft vs Host Disease · United States2CompletedMesoblastApr 25, 200611
NCT00136903Graft vs Host Disease · United States2CompletedMesoblastJul 28, 200632

How it is read

Names in the registry

  • “Prochymal®”, 5 entries
  • “Remestemcel-L-rknd”, 1 entry
  • “PROCHYMAL®”, 1 entry
  • “Prochymal™”, 1 entry
  • “Prochymal”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.